Oncology Dashboard for the Improvement of Operational Efficiency and Patients Outcomes in Patients With Sarcoma

NCT05216029 | Completed

• 2 other identifiers: 2014-0707NCI-2021-09453
• Study Type: interventional
• Target: 92
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial investigates whether measuring and presenting information about a patient's cancer treatment to them, their doctor, and their radiologist using a tool called an "oncology dashboard" may help patients understand the disease better and help the patient's medical team manage their care more efficiently. The oncology dashboard tool may help patients understand the disease better and may help improve the efficiency of their medical care.

Conditions

Sarcoma

Outcome Measures

Primary Outcomes (1)

• Time to complete medical oncology review (oncology workflow)

  through study completion, an average of 1 year

Study Arms (2)

Group I (oncology dashboard)

EXPERIMENTAL

Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.

Other: Informational Intervention; Other: Questionnaire Administration

Group II (standard of care)

EXPERIMENTAL

Patients receive standard of care.

Other: Best Practice; Other: Questionnaire Administration

Interventions

Best Practice OTHER

Receive standard of care

Also known as: standard of care, standard therapy

Group II (standard of care)

Informational Intervention OTHER

View oncology dashboard

Group I (oncology dashboard)

Questionnaire Administration OTHER

Ancillary studies

Group I (oncology dashboard); Group II (standard of care)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with sarcoma on active chemotherapy/targeted therapy
• Patients must have stable to mildly progressive disease or better on baseline assessment
• Baseline measurement and follow-up measurement have to be performed on the same treatment for consistency. If patients with progressive disease are included into the study at baseline, follow-up measurement will be on a different treatment. Invariable, initiation of a new treatment, in the setting of progressive disease, lengthens oncology workflow which would affect the post measurement
• Patients must have been on the same treatment for at least 6 weeks
• Patients must have at least 3 prior imaging studies of the same body part/tracked lesion/area of interest separated by 6 weeks or more between studies
• Patients should be continuing same therapy for the next 6-8 weeks
• Patients must have plan for follow-up with imaging studies at MD Anderson Cancer Center (MDACC) while on therapy
• Patients who are receiving therapy outside of MDACC but having their follow-up imaging at MDACC are eligible
• \>= 18 years of age

You may not qualify if:

• Expected survival of less than 8 weeks
• Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 4
• Non- English-speaking patients and patients with cognitive impairment who cannot complete the questionnaire

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

• M D Anderson Cancer Center

MeSH Terms

Conditions

Sarcoma

Interventions

Practice Guidelines as Topic; Standard of Care

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Intervention Hierarchy (Ancestors)

Guidelines as Topic; Quality Assurance, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation; Quality Indicators, Health Care

Study Officials

• Vinod Ravi

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 18, 2022
• First Posted: January 31, 2022
• Study Start: October 1, 2015
• Primary Completion: March 18, 2026
• Study Completion: March 18, 2026
• Last Updated: April 1, 2026

Record last verified: 2026-03

Locations

US (1)